Hit By U.S. Economic Tremors, Collapse In Biologics Business, WuXi PharmaTech Posts Massive Loss For 2008, American Unit AppTec Deeply Devalued
This article was originally published in PharmAsia News
Executive Summary
BEIJING - Battered in succession by the unstable U.S. economy, faltering biologics customers and mounting losses by American subsidiary AppTec Laboratory Services, WuXi PharmTech reported a net loss of more than $60 million for 2008
You may also be interested in...
WuXi Apptec Plots Future, But Is It Overreaching?
WASHINGTON - WuXi Apptec CEO Ge Li believes the company will benefit greatly from ramping up capability and capacity to meet growing demand, but analysts question whether the increased capacity will be fully utilized
WuXi Apptec Plots Future, But Is It Overreaching?
WASHINGTON - WuXi Apptec CEO Ge Li believes the company will benefit greatly from ramping up capability and capacity to meet growing demand, but analysts question whether the increased capacity will be fully utilized
WuXi PharmaTech Marks Second Quarter Of Earnings Rebound Following 2008's Devastating Loss, Opens New Drug Safety Testing Center
BEIJING - After recording a massive loss for 2008, WuXi PharmaTech, China's leading pharmaceutical contract research organization, posted a second consecutive quarter of earnings growth in the April-June period of this year